Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
6,881 results in Europe PMC
PubMed plus preprints and full-text open access papers. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- Single nucleotide polymorphisms associated with glucocorticoid treatment response in immune thrombocytopenia: A systematic review and meta-analysis.
Sarbaz-Jeda E, Alemohammad SS, Soleimani Samarkhazan H, Mohammadyari A, Karami A, Manafi Shabestari R, Rostami M. · Cytokine · 2026 · cited 0 timesmeta-analysis, systematic review
- Association between the interleukin 17F rs763780 polymorphism and immune thrombocytopenia risk: A systematic review and meta-analysis.
Fan L, Huai Q, Zhang Z, Liu Z, Zhang X, Wu W, Ye H, Wang S, Zhao Z, Yang X, Wang L, Gao S. · Cytokine · 2026 · cited 0 timesmeta-analysis, systematic review
- A Phase 2 Randomized Trial of Mezagitamab in Primary Immune Thrombocytopenia.
Kuter DJ, Miura K, Patriarca A, Pulanić D, Radinoff A, Sapunarova K, Syrigou A, Yang R, Nguyen VA, Skelton E, Wang S, Yee DL, Patwari P, Mezagitamab ITP Phase 2 Trial Investigators. · N Engl J Med · 2026 · cited 2 timesclinical trial, phase ii, multicenter study
- Spleen tyrosine kinase inhibitors for immune thrombocytopenia: A meta-analysis of randomized controlled trials.
Pereira NLC, Santos LOS, Oliveira Torres FB, Costa MV, Saldanha A. · Transfus Apher Sci · 2026 · cited 0 timesmeta-analysis, systematic review
- BCMA-directed CAR T-cell therapy induces durable drug-free remission in refractory primary immune thrombocytopenia.
Shu J, Xu M, Li P, Xie W, Liu L, Li H, Bussel JB, Hu Y, Mei H. · Blood · 2026 · cited 0 timesclinical trial, phase i
- Clinical activity and safety of rilzabrutinib in patients with previously treated immune thrombocytopenia (LUNA3): results from the open-label period of a phase 3 trial.
Kuter DJ, Ghanima W, Cooper N, Liebman HA, Zhang L, Hu Y, Miyakawa Y, Hütter-Krönke ML, Pascual-Izquierdo C, Lucchini E, Audia S, Cordoba M, Krenz H, Yao M, Daak A. · Lancet Haematol · 2026 · cited 0 timesclinical trial, phase iii, multicenter study
- Helicobacter pylori eradication for immune thrombocytopenia reduces non-response and raises platelet counts: Meta-analysis of randomized trials.
Hattab M, Milhem F, Jallad H, Suleiman M, Albada H, Khaled A, Saife S, Hallak M, Saife S, Abualhommos F, Bdair M. · Ann Hematol · 2026 · cited 0 timesOpen accessmeta-analysis, systematic review
- Ianalumab plus Eltrombopag in Immune Thrombocytopenia.
Cuker A, Stauch T, Cooper N, Al-Samkari H, Michel M, Ghanima W, Urban P, Fronczek J, Foster M, Weill M, Zhang L, Hou M, Zander T, Sharif A, Sun J, Nath UK, Schutgens R, Rossi E, Deleu L, Červinek L, Yoon JH, Chang H, Ruchutrakool T, Iino M, Goto T, Zaja F, VAYHIT2 Investigators. · N Engl J Med · 2026 · cited 3 timesclinical trial, phase iii, multicenter study
- The thrombotic burden of high-risk immune thrombocytopenia patients receiving second-line treatments: a systematic review.
Tarasconi E, Clerici B, Marcucci G, Pontisso E, Mondini C, Pisetta C, Birocchi S, Schioppo T, Podda GM. · Rheumatology (Oxford) · 2026 · cited 0 timesOpen accesssystematic review, review-article
- Low-dose baricitinib plus danazol in primary immune thrombocytopenia: a randomized, controlled phase 2 trial.
Zhao P, An ZY, Fu HX, Wang Y, Feng GS, Liu HX, Liu DH, Liu Y, Zhou HB, Liu H, Wang Z, Dong YJ, Jing HM, Li ZL, Li LH, Dou LP, Huang QS, Wu J, Yang LP, Jin Y, Li ZX, Wang CC, Chen Q, Zhu XL, He Y, Zhang YY, Jiang Q, Jiang H, Lu J, Chang YJ, Zhao XY, Huang XJ, Zhang XH. · Nat Commun · 2026 · cited 0 timesOpen accessclinical trial, phase ii, research support, non-u.s. gov't
- Real-World Safety and Efficacy of Avatrombopag in Adults with Immune Thrombocytopenia: A Systematic Review and Meta-Analysis.
Lozano ML, Valcarcel D. · Eur J Haematol · 2026 · cited 0 timesmeta-analysis, systematic review
- Safety and efficacy of daratumumab in immune thrombocytopenia.
Tsykunova G, Holme PA, Tran HTT, Frederiksen H, Tjønnfjord E, Munthe LA, Drivet E, Kared H, Sørvoll IH, Ahlen MT, Mahévas M, Michel M, Bussel J, Kuter DJ, Anderson Tvedt TH, Ghanima W. · Blood Adv · 2026 · cited 20 timesOpen accessclinical trial, phase ii, multicenter study
- All-<i>Trans</i> Retinoic Acid plus Eltrombopag for Refractory/Relapsed Immune Thrombocytopenia.
Fu H, An Z, Li M, Liu Y, Liu H, Feng R, Wang Z, Zhang G, Wang J, Yang L, Huang Q, Zhao P, Zang M, Wang C, He Y, Zhu X, Liu H, Wang Y, Xu L, Kong Y, Chang Y, Zhao X, Wang Y, Feng G, Huang X, Zhang X. · NEJM Evid · 2026 · cited 0 timesmulticenter study, randomized controlled trial
- Efficacy and safety of IgG-pathway inhibitors in adult immune thrombocytopenia: A systematic review and meta-analysis with subgroup analyses of FcRn and SYK inhibitors.
Almasalma M, Kandil AH, Al-Qadi MH, Maarouf ML, Altaamreh SM, Soliman WA, Mohamed AS, Boshta A, Almosilhy NA, Alsalhen BZ, Chukr M. · Cytokine · 2026 · cited 0 timesmeta-analysis, systematic review
- Low-dose oral nicotinamide mononucleotide for immune thrombocytopenia: a phase 1/2 trial.
Li H, Xu Y, Chen Y, Ji L, Xu Y, Zheng W, Sun T, Fu R, Pei X, Liu X, Xue F, Liu W, Wang W, Chi Y, Yang R, Wei J, Zhang L. · Nat Med · 2026 · cited 4 timesclinical trial, phase ii, clinical trial, phase i
- Avatrombopag for persistent and chronic immune thrombocytopenia in children: A post hoc analysis of clinical characteristics of response from a phase 3b clinical trial.
Grace RF, Leblebisatan G, Aydinok Y, Unal S, Grainger J, Grimes AB, Lambert MP, Zhang J, Jamieson BD, Sattar F, Kolodny S, Vredenburg M, AVA‐PED‐301 Study Group. · Br J Haematol · 2026 · cited 0 timesOpen accessclinical trial, phase iii, multicenter study
- A multicentre randomized open-label phase 2 trial of dexamethasone plus glycyrrhizinate versus dexamethasone in newly diagnosed immune thrombocytopenia.
Wang H, Wang R, Yuan C, Bi K, Xiao T, Teng Q, Wang H, Yu J, Hou M, Hou Y. · Br J Haematol · 2026 · cited 0 timesclinical trial, phase ii, comparative study
- Immune Thrombocytopenia in Low- and Middle-Income Countries: A Systematic Review.
Gurumurthy G, Kropidlowska J, Khachatryan H, Ogweno G, Nwagha T, Thachil J. · Clin Appl Thromb Hemost · 2026 · cited 0 timesOpen accesssystematic review
- Efficacy and Safety of Romiplostim Versus Placebo in Immune Thrombocytopenia: A Systematic Review and Meta-Analysis.
Ahmed H, Khan MS, Zulfiqar D, Mehmood K, Farhan K, Hassan SA, Shaikh F, Lutuf U, Aqsa, Waafira A. · Clin Appl Thromb Hemost · 2026 · cited 0 timesOpen accessmeta-analysis, systematic review
- Efficacy and safety of dapsone in adult immune thrombocytopenia: a systematic review and meta-analysis.
Khan I, Qasim SA, Rath S, Mumtaz Malik H, Rehman S, Aleem S, Javaid H, Saleh AO, Halim SA, Kamil KA. · Eur J Med Res · 2025 · cited 1 timesOpen accessmeta-analysis, systematic review
- Eltrombopag for Newly Diagnosed Pediatric Immune Thrombocytopenia Requiring Treatment: The PINES Randomized Clinical Trial.
Shimano KA, Grimes AB, Kaicker S, Shah SJ, Gunn E, Bhat RV, Kochhar M, Rothman JA, Rose MJ, Briones M, Nakano TA, Lebensburger JD, Lambert MP, Fritch Lilla SA, Jesudas R, Lee-Miller CA, Thompson AA, Rifkin-Zenenberg S, Majumdar S, Crary SE, Hege K, Ford JB, Bies JJ, Fort J, Wynn TT, Hsieh L, Ruiz ME, Dinu B, Wong JMW, Kao PC, Kim TO, Arnold SD, Bennett CM, Despotovic JM, Klaassen RJ, Neufeld EJ, Neunert CE, London WB, Grace RF. · JAMA · 2025 · cited 6 timesclinical trial, phase iii, multicenter study
- High pretreatment peripheral blood T-cell receptor clonality as a predictor of prolonged response in immune thrombocytopenia.
Schmidt-Barbo P, Schultheiss C, Jauch AJ, Simnica D, Silling G, Hänel M, Chromik J, Stauch T, Trautmann-Grill K, Repp R, Schulte C, Fleischmann B, Welslau M, Stauch M, Quiering C, Richter F, Tesanovic T, Jahn S, Holbro A, Passweg JR, Matzdorff A, Rummel M, Meyer O, Nimmerjahn F, Binder M. · Br J Haematol · 2026 · cited 1 timesOpen accessletter, multicenter study
- Clinical efficacy of Guishao Shengxue decoction in the treatment of pediatric immune thrombocytopenia: A randomized controlled trial.
Wang W, Xie X, Cui S, Xue L. · Explore (NY) · 2025 · cited 0 timesrandomized controlled trial
- The interleukin-1 receptor antagonist gene VNTR polymorphism confers a genetic contribution to the risk of immune thrombocytopenia purpura: A systematic review and meta-analysis.
Wei H, Xie Y, Huai Q, Hua Z, Yang X, Chen L, Kong Y, Xue W, Zhao C, Gao S, Yang X. · Cytokine · 2026 · cited 0 timesmeta-analysis, systematic review
- Efficacy and safety of eltrombopag in combination with dexamethasone as first-line treatment in adult patients with newly diagnosed immune thrombocytopenia.
Jauch AJ, Schmidt-Barbo P, Schultheiss C, Silling G, Hänel M, Chromik J, Stauch T, Trautmann-Grill K, Repp R, Schulte C, Fleischmann B, Welslau M, Stauch M, Quiering C, Richter F, Tesanovic T, Jahn S, Bignucolo O, Holbro A, Passweg JR, Matzdorff A, Rummel M, Meyer O, Nimmerjahn F, Binder M. · Br J Haematol · 2026 · cited 2 timesmulticenter study, randomized controlled trial
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.